Dapagliflozin, an SGLT2 inhibitor, for diabetes

The Lancet

Volumn 375, Issue 9733, 2010, Pages 2196-2198

  Hanefeld, Markolf ^a   Forst, Thomas ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Institute for Clinical Research and Development   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSMOTIC DIURESIS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RENAL DIABETES; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 77953860370     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60749-0     Document Type: Note

References (11)

1. Gerich J.E. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27 (2010) 136-142
2. Santer R., Kinner M., Lassen C.L., et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14 (2003) 2873-2882
3. Neumiller J.J., White J.R., and Campbell R.K. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70 (2010) 377-385
4. Ehrenkranz J.R., Lewis N.G., Kahn C.R., and Roth J. Phlorizin: a review. Diabetes Metab Res Rev 21 (2005) 31-38
5. Bailey C.J., Gross J.L., Pieters A., Bastien A., and List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010) 2223-2233
6. Idris I., and Donnelly R. Sodium-glucose co-trainsporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11 (2009) 79-88
7. Geerlings S.E., Brouwer E.C., van Kessel K.C.P.M., Gaastra W., Stolk R.P., and Hoepelman A.I. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 30 (2003) 995-1001
8. Brown J.S., Wessels H., Chancellor M.B., et al. Urological complications of diabetes. Diabetes Care 28 (2005) 177-185
9. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
10. Home P.D., Pocock S.J., Beck-Nielsen H., et al., for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009) 2125-2135
11. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 26 (2009) 1185-1192